Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 4/20 | 0.66 |
| ▸ | PPARG | P37231 | 3/20 | 0.66 |
| ▸ | PPARA | Q07869 | 3/20 | 0.66 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 6/20 | 0.52 |
| ▸ | ICMT | O60725 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257266 | 0.92 | PPARD (0.69) | PPARDPPARGPPARALTB4RLTB4R2 | |
| SCHEMBL13930965 | 0.92 | PPARD (0.77) | PPARDPPARGPPARALTB4RLTB4R2 | |
| SCHEMBL8179565 | 0.90 | ICMT (0.58) | PPARDPPARGPPARAALDH1A1LMNA | |
| SCHEMBL8172515 | 0.88 | LMNA (0.68) | PPARDPPARGPPARALTB4RLTB4R2 | |
| SCHEMBL8178171 | 0.88 | LMNA (0.57) | PPARDPPARGPPARALTB4RLTB4R2 | |
| SCHEMBL8174606 | 0.88 | PPARD (0.72) | PPARDPPARGPPARALTB4RLTB4R2 | |
| SCHEMBL8174648 | 0.88 | PLA2G2A (0.61) | PPARDPPARGPPARAALDH1A1LMNA | |
| SCHEMBL8173522 | 0.87 | PPARD (0.54) | PPARDPPARGPPARALTB4RLTB4R2 | |
| SCHEMBL8171659 | 0.87 | PPARD (0.82) | PPARDPPARGPPARALTB4RLTB4R2 | |
| SCHEMBL7679351 | 0.86 | ALDH1A1 (0.62) | PPARDPPARGPPARAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | PPARD 3946/4885PPARG 3213/4885PPARA 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.